Navigation Links
Genzyme Reports Strong First-Quarter Growth
Date:4/23/2008

p> patients. Preliminary data from this trial will be presented at the

American Society of Clinical Oncology meeting in June.

Genzyme is developing a new filing for the adult AML indication in

Europe. This follows its withdrawal of Bioenvision's marketing

application, which, as expected, an advisory committee deemed

insufficient to support approval. Genzyme expects to make a new

submission as early as the fourth quarter of this year that will

include a more robust data package from Genzyme sponsored studies.

Alemtuzumab for multiple sclerosis

-- Final, three-year efficacy and safety data from the Phase 2 trial

comparing alemtuzumab with Rebif (interferon beta-1a) for the treatment

of relapsing-remitting multiple sclerosis were presented last week

during a scientific platform session at the American Academy of

Neurology meeting by Dr. Alasdair Coles. These results confirm all

trends observed in the one- and two-year interim analyses. The two

ongoing Phase 3 trials further examining the efficacy and safety of

alemtuzumab for the treatment of MS are progressing. These two studies

are currently enrolling patients at sites in the United States, Europe,

Latin America and Australia. Genzyme believes that alemtuzumab has the

potential to be the best therapy in a market for MS drugs that is

projected to reach $8-9 billion annually when the treatment is expected

to be ready for launch in 2011-2012. Alemtuzumab is being developed in

collaboration with Bayer Schering Pharma AG, Germany.

Genz-112638 for Gaucher disease

-- Genzyme is making excellent progress in developing the small molecule

Genz-112638, a novel oral therapy intended for the treatment of Gaucher

disease. Initial results released one year ago for the first group of

stud
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Genzyme to Build New R&D Center in Beijing
2. Genzyme Provides Update on Myozyme(R) Manufacturing
3. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
4. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
5. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
6. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
7. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
8. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
9. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
10. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
11. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Israel , Aug. 31, 2015 ... Dario™ Diabetes Management Solution, today announced it recently ... million. Funds will be used to support the ... the Dario, a mobile, cloud-based, diabetes management solution ... stylish, ,all-in-one, pocket-sized, blood glucose monitoring device, and ...
(Date:8/31/2015)... ... August 31, 2015 , ... There’s a new treatment option ... the first commercially available new FDA approved system in the last 14 years, and ... the high Amenorrhea (zero bleeding) rate of 66%, the high Patient Satisfaction rate of ...
(Date:8/28/2015)... 2015 According to a new ... Storage Systems, Thawing Equipment, Alarms), by Biospecimen (Human Tissue, ... End User - Global Forecast to 2020", published by ... USD 3,731.03 Million by 2020 from USD 2,150.48 Million ... 2015 and 2020. Browse 74 Tables ...
(Date:8/28/2015)... ... 2015 , ... Riordan-McKenna Institute founders, stem cell ... the use of sterile, dehydrated amniotic tissue AlphaPATCH™ developed by Amniotic Therapies ... knee wound. , The case involved a 78-year-old male, who presented with a ...
Breaking Biology Technology:LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 2LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 3LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 4U.S. FDA Approves Minerva Endometrial Ablation System 2U.S. FDA Approves Minerva Endometrial Ablation System 3Biopreservation Market Worth 3,731.03 Million USD by 2020 2Biopreservation Market Worth 3,731.03 Million USD by 2020 3Biopreservation Market Worth 3,731.03 Million USD by 2020 4Biopreservation Market Worth 3,731.03 Million USD by 2020 5Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 2Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 3Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 4
... At a meeting of the,Board of ... ), held today, a dividend of ... outstanding shares of Preferred Stock was,declared ... stockholders of record at the close,of ...
... Aida,Pharmaceuticals, Inc. (OTC Bulletin Board: AIDA) today announced ... ended September 30, 2007. Net,revenues totaled $7,373,770 for the ... period in 2006. Gross profit decreased by 2.66% due ... sales from Aida,s,transfusion and injection forms of etimicin sulfate ...
... Million Financing, WOBURN, Mass., Nov. 15 BioVex ... the treatment and,prevention of cancer and infectious disease, announced ... the completion of a,venture debt transaction, raising a total ... the capital to complete its preparations for, and,to commence, ...
Cached Biology Technology:Aida Files 10Q 2Aida Files 10Q 3Aida Files 10Q 4BioVex Closes Second Round of Series E Financing 2
(Date:8/18/2015)... PRINCETON, N.J. , Aug. 18, 2015 ... be a key contributor to the Submission ... hosted by IRISS, a non-profit forum. Dedicated to ... IRISS provides a neutral platform for industry, ... to share information and work towards a ...
(Date:8/12/2015)... Aug. 12, 2015   MedNet Solutions , an ... spectrum of clinical research, is proud to announce that ... comprehensive SaaS-based eClinical technology platform, has led the way ... two quarters of 2015.   Q2 2015 and Q1 ... measured by contract value sold in the company,s 15 ...
(Date:8/12/2015)... Aug. 12, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced that four of its fingerprint ... have officially been named FIDO Certified™ by the ... the certification, Synaptics, Natural ID™ fingerprint solutions are ... Framework (UAF) standard and are interoperable among other ...
Breaking Biology News(10 mins):Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3MedNet Solutions Experiences Explosive Corporate Growth 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3
... , June 4, 2013  With invasions of computer systems ... Identify Security Software Inc. ( www.identifyss.com ) today announced ... http://photos.prnewswire.com/prnh/20130604/FL25436LOGO ) "Identify Security Software ... way for businesses and institutions to manage and control ...
... and NEW ORLEANS , June 3, 2013 ... Microsoft demonstrates an FPC fingerprint touch sensor in combination with a ... demonstrations showcase a number of innovative online use cases using FPC,s ... to sign on to their Microsoft account, make online payments and ...
... the Duke-NUS Graduate Medical School (Duke-NUS) in Singapore has ... protein linked to stem cell-like behavior in terminal-stage chronic ... that may extend the survival of these patients. ... Proceedings of the National Academy of Sciences , is ...
Cached Biology News:Identify Security Software to Make Cyberspace Secure 'Once And For All' 2Identify Security Software to Make Cyberspace Secure 'Once And For All' 3Fingerprint Cards (FPC) Demonstrates Fingerprint Biometric Touch Sensor for Microsoft Windows 8.1 2Singapore research team identifies new drug target in deadly form of leukemia 2
Sheep polyclonal to hCG beta core fragment ( Abpromise for all tested applications). Antigen: Full length native protein (purified) from human urine. Entrez GeneID: 1082 Swiss Protein ID...
Evolutionarily conserved signaling intermediate in Toll pathway...
Anti-MMP-25 (Membrane-type MMP-6, Mt6MMP), hinge region; rabbit host...
Anti-MMP-25 (Membrane-type MMP-6, Mt6MMP), hinge region; rabbit host...
Biology Products: